Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Anthony John Iafrate, M.D.,Ph.D.

Co-Author

This page shows the publications co-authored by Anthony Iafrate and Alejandro Balazs.
Connection Strength

2.434
  1. Comparative Immunogenicity and Effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 Vaccines. J Infect Dis. 2022 Apr 01; 225(7):1141-1150.
    View in: PubMed
    Score: 0.249
  2. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell. 2022 02 03; 185(3):457-466.e4.
    View in: PubMed
    Score: 0.245
  3. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. medRxiv. 2021 Dec 14.
    View in: PubMed
    Score: 0.244
  4. Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2 and Ad26.COV2.S COVID-19 vaccines. medRxiv. 2021 Oct 13.
    View in: PubMed
    Score: 0.241
  5. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021 Apr 29; 184(9):2523.
    View in: PubMed
    Score: 0.233
  6. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. medRxiv. 2021 Mar 12.
    View in: PubMed
    Score: 0.231
  7. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021 04 29; 184(9):2372-2383.e9.
    View in: PubMed
    Score: 0.231
  8. COVID-19-neutralizing antibodies predict disease severity and survival. Cell. 2021 01 21; 184(2):476-488.e11.
    View in: PubMed
    Score: 0.228
  9. COVID-19 neutralizing antibodies predict disease severity and survival. medRxiv. 2020 Oct 20.
    View in: PubMed
    Score: 0.225
  10. T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals. Cell. 2022 Mar 31; 185(7):1259.
    View in: PubMed
    Score: 0.062
  11. T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals. Cell. 2022 03 17; 185(6):1041-1051.e6.
    View in: PubMed
    Score: 0.062
  12. T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all prior infected and vaccinated individuals. medRxiv. 2022 Jan 05.
    View in: PubMed
    Score: 0.061
  13. Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer. Cancer Cell. 2022 01 10; 40(1):103-108.e2.
    View in: PubMed
    Score: 0.061
  14. Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study. J Clin Oncol. 2022 01 01; 40(1):12-23.
    View in: PubMed
    Score: 0.061
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.